The peak sales forecast for AstraZeneca Efzimfotase Alfa is expected to reach 5 billion US dollars, and executives believe this bone disease drug is expected to be approved.

Zhitongcaijing · 1d ago
The peak sales forecast for AstraZeneca Efzimfotase Alfa is expected to reach 5 billion US dollars, and executives believe this bone disease drug is expected to be approved.